Product Description
Reference Standards &Impurity
AI Product Description
*The following content is generated by AI and is for reference only.
Erythromycin is a widely utilized macrolide antibiotic derived from the soil bacterium *Saccharomyces erythraeus*. Its molecular formula is C37H67NO13, and it is identified by the CAS registry number 114-07-8. Structurally, this compound features a large macrocyclic lactone ring to which two sugar moieties are attached, a configuration essential for its biological activity. As one of the first macrolides discovered, Erythromycin revolutionized the treatment of bacterial infections, particularly for patients with penicillin allergies, establishing a cornerstone in modern antimicrobial therapy.
The primary mechanism of action involves the inhibition of bacterial protein synthesis. It binds reversibly to the 50S subunit of the bacterial ribosome, thereby blocking the translocation step during peptide chain elongation. This effectively halts the growth of susceptible organisms rather than killing them directly, classifying it as a bacteriostatic agent at standard doses, though it can be bactericidal against certain pathogens at higher concentrations. Its spectrum of activity covers a broad range of Gram-positive bacteria, including Streptococcus and Staphylococcus species, as well as some Gram-negative organisms like Neisseria and Bordetella pertussis. Additionally, it is effective against atypical pathogens such as Mycoplasma pneumoniae, Chlamydia trachomatis, and Legionella pneumophila.
Clinically, Erythromycin is prescribed for respiratory tract infections, skin and soft tissue infections, whooping cough, and sexually transmitted diseases like chlamydia. It is also used prophylactically in specific surgical procedures to prevent endocarditis. The drug is available in various formulations, including oral tablets, capsules, suspensions, and intravenous solutions, often formulated as esters or salts to improve stability and absorption. Despite its efficacy, common side effects include gastrointestinal disturbances such as nausea, vomiting, and abdominal pain. Furthermore, Erythromycin is a potent inhibitor of cytochrome P450 enzymes, leading to significant drug-drug interactions that require careful clinical monitoring. While newer macrolides have emerged with better pharmacokinetic profiles, Erythromycin remains a vital therapeutic option globally due to its established safety record and cost-effectiveness in treating diverse infectious diseases.